Binge Eating Disorder (BED)
- Definition & Facts for Binge Eating Disorder – NIH Patient Education
- Weight Stigma in the Practice of Psychotherapy for Binge Eating Disorder: Guidance for Professionals
- Weight Stigma in Kids’ Programs and Schools: Guidance for Kids’ Programs Leaders
- DSM-5 Criteria for Binge Eating Disorder NOTE: This tool is best viewed in Google Chrome or Internet Explorer
- Binge Eating Disorder (BED) – A Comorbid Conundrum
- Binge Eating Disorder Resources
Bipolar Disorder
- Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial
- Evaluating lurasidone as a treatment option for bipolar disorder
- Bipolar Disorder Diagnosis and Treatment for Patients
- Treatment of Bipolar Depression in Children and Adolescents
- Understanding Bipolar Depression – Patient Handout
Depression
- National Alliance on Mental Health (NAMI) – Depression
- Re-examine Depression: Videos & resources
- NIH Information and Resources on Depression (Including Perinatal Depression)
- U.S Preventive Services Task Force: Perinatal Depression – Preventive Interventions
- CDC Patient Information and Resources: Depression During and After Pregnancy
- Feeling sad after your baby is born? Video from the American Academy of Pediatrics
- Perinatal depression: A review
- Development of neuroactive steroids for the treatment of postpartum depression
- Patient-Specific Considerations, the GABA Pathway, and New Clinical Trial Data on Neuroactive Steroids in MDD and PPD
- Brexanolone Prescribing Information
- Safety of Brexanolone in Adults with Postpartum Depression: Postmarketing Surveillance Data
- GABAkines – Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors
- Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program
- Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials
- Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial
- Zuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
- Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial
- Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression
- Allopregnanolone in postpartum depression: Role in pathophysiology and treatment
- BPRS Brief Psychiatric Rating Scale
- PHQ-9 Quick Depression Assessment
- Montgomery-Asberg Depression Rating Scale
- Edinburgh Postnatal Depression Scale
- Depression – stopping your medicine – Patient Handout
- Major Depressive Disorder – Patient Handout
- What are the Causes of Depression? – Patient Handout
Mood Disorders
Parkinson’s Disease Psychosis
- QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson’s Disease Psychosis: A Narrative Review
- Depression in Patients with Parkinson’s Disease: Current Understanding of its Neurobiology and Implications for Treatment
Schizophrenia
- Emerging Treatments in Schizophrenia
- Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention
- A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
- Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
- Trace Amine-Associated Receptor 1 (TAAR1): Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities
- Xanomeline–Trospium for Schizophrenia
- Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
- New Second-generation Antipsychotics
- Long-acting Injectable Second Generation Antipsychotics
- Examples of Neurocognitive Assessments that Can Be Completed at the Bedside
- Motivational Interviewing: A tool to improve medication adherence?
- Living with Schizophrenia – Patient Handout
- Antipsychotics Fact Sheet – Patient Handout
- Support Groups and Supportive Resources – Patient Handout
- Approach to Schizophrenia Management At-A-Glance – Patient Handout
- Schizophrenia: Recognizing the Symptoms and Getting Treatment – Patient Handout
Substance Use Disorders
- Providers’ Clinical Support System for Opioid Therapies (PCSS-O): Educational Resources
- Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
- Opioid Treatment Program (OTP) Certification
- Medication Assisted Treatment (MAT) Certification
